R
Rachel B. Wagman
Researcher at Amgen
Publications - 91
Citations - 4324
Rachel B. Wagman is an academic researcher from Amgen. The author has contributed to research in topics: Denosumab & Osteoporosis. The author has an hindex of 27, co-authored 82 publications receiving 3533 citations. Previous affiliations of Rachel B. Wagman include Magna Græcia University & Stanford University.
Papers
More filters
Journal ArticleDOI
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone,Rachel B. Wagman,Maria Luisa Brandi,Jacques P. Brown,Roland Chapurlat,Steven R. Cummings,Edward Czerwiński,Astrid Fahrleitner-Pammer,David L. Kendler,Kurt Lippuner,Jean-Yves Reginster,Christian Roux,Jorge Malouf,Michelle N. Bradley,Nadia Daizadeh,Andrea Wang,P. Dakin,Nicola Pannacciulli,David W. Dempster,S. Papapoulos +19 more
TL;DR: The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165·3 to 95·9 per 100 participant-years over the course of 10 years, and serious adverse event rates were generally stable over time.
Journal ArticleDOI
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Jacques P. Brown,Richard L. Prince,Chad L. Deal,Robert R. Recker,Douglas P. Kiel,Luiz H. De Gregorio,Peyman Hadji,Lorenz C. Hofbauer,Jose M. Álvaro-Gracia,H. Wang,M. Austin,Rachel B. Wagman,Rachel B. Wagman,Richard Newmark,Cesar Libanati,Javier San Martin,Henry G. Bone +16 more
TL;DR: Denosumab showed significantly larger gains in BMD and greater reduction in bone turnover markers compared with alendronate and the overall safety profile was similar for both treatments.
Journal ArticleDOI
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos,Kurt Lippuner,C. Roux,C J F Lin,David L. Kendler,E. M. Lewiecki,M. L. Brandi,Edward Czerwiński,Edward Franek,Peter L. Lakatos,Carlos Mautalen,Salvatore Minisola,Jean-Yves Reginster,S Jensen,Nadia Daizadeh,A. Wang,M Gavin,Cesar Libanati,Rachel B. Wagman,Henry G. Bone +19 more
TL;DR: Denosumab treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile.
Journal ArticleDOI
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
Henry G. Bone,Roland Chapurlat,Maria-Luisa Brandi,Jacques P. Brown,Edward Czerwiński,Marc-Antoine Krieg,Dan Mellström,Sebastião Cezar Radominski,Jean-Yves Reginster,Heinrich Resch,José Andrés Román Ivorra,Christian Roux,Eric Vittinghoff,Nadia Daizadeh,Andrea Wang,Michelle N. Bradley,N. Franchimont,Michelle Geller,Rachel B. Wagman,Steven R. Cummings,Socrates E. Papapoulos +20 more
TL;DR: Denosumab treatment for 6 years remained well tolerated, maintained reduced bone turnover, and continued to increase BMD; fracture incidences remained low and below the rates projected for a virtual placebo cohort.
Journal ArticleDOI
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
Ian R. Reid,Paul D. Miller,Jacques P. Brown,David L. Kendler,Astrid Fahrleitner-Pammer,Ivo Valter,Katre Maasalu,Michael A. Bolognese,Grattan Woodson,Henry G. Bone,Beiying Ding,Rachel B. Wagman,Javier San Martin,Michael S. Ominsky,David W. Dempster +14 more
TL;DR: Denosumab markedly reduces bone turnover and also reduces fracture numbers, and indices of bone turnover tended to be lower in the denosumAB group than in the alendronate group.